IgA Nephropathy Pipeline Appears Promising With 25+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

DelveInsight's, "IgA Nephropathy Pipeline Insight, 2025," report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the IgA Nephropathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in IgA Nephropathy Research. Learn more about our innovative pipeline today! @ IgA Nephropathy Pipeline Outlook- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the IgA Nephropathy Pipeline Report
• In July 2025, Novartis Pharmaceuticals announced a study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.
• In July 2025, Calliditas Therapeutics AB conducted a clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice.
• In July 2025, Hoffmann-La Roche announced a study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.
• In July 2025, Biogen conducted a study is to evaluate the efficacy of felzartamab compared to placebo on proteinuria in participants with Immunoglobulin A nephropathy (IgAN). The main secondary objective of the study is to evaluate the efficacy of felzartamab compared to placebo on kidney functions in participants with IgAN. The additional secondary objectives are to evaluate the efficacy of felzartamab compared to placebo on additional clinical endpoints and to assess the pharmacokinetics (PK) and immunogenicity of felzartamab.
• In July 2025, Novartis Pharmaceuticals announced a study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. The study aims to provide insights into the treatment's systemic and kidney-specific aspects by quantifying the change in mesangial C3c containing fragments deposition, as an indicator of complement activation, and evaluating a variety of biomarkers related to kidney function, damage, and disease progression, including but not limited to Oxford MEST-C score.
• DelveInsight's IgA Nephropathy pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for IgA Nephropathy treatment.
• The leading IgA Nephropathy Companies such as Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Selecta Biosciences, and Shanghai Alebund Pharmaceuticals and others.
• Promising IgA Nephropathy Pipeline Therapies such as LNP023, Blisibimod, Intravenous Rituximab, BION-1301, Atrasentan, TARPEYO®, HRS-5965 and others.

Stay informed about the cutting-edge advancements in IgA Nephropathy treatments. Download for updates and be a part of the revolution in Genito Urinary System and Sex Hormones Care @ IgA Nephropathy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

IgA Nephropathy Emerging Drugs Profile
• Atrasentan: Chinook Therapeutics
Atrasentan is a potent and selective inhibitor of the endothelin A receptor (ETA) that has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function. Chinook selected IgAN as the lead indication for atrasentan due to the role of ETA activation in driving proteinuria, mesangial cell activation, kidney inflammation and fibrosis, the hallmarks of IgAN disease progression. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of IgA Nephropathy.

• SHR-2010: Guangdong Hengrui Pharmaceutical Co., Ltd.
SHR-2010 is a drug being studied for the treatment of Primary IgA Nephropathy. It is an injection developed by Guangdong Hengrui Pharmaceutical Co., Ltd., currently in Phase II of research. The drug is aimed at inhibiting MASP2protein. Clinical trials are ongoing to evaluate the efficacy, safety, and pharmacokinetics of SHR-2010 in patients with Primary IgA Nephropathy.

• TAK-079: Takeda
TAK-079, also known as mezagitamab, targets CD38-expressing cells, including plasmablasts, plasma cells, and natural killer cells, leading to their depletion. The rationale for using TAK-079 in IgA nephropathy is that by reducing plasma cells responsible for producing the abnormal IgA1 protein, it may help prevent the formation of pathogenic immune complexes and subsequent kidney injury. In a Phase 1b clinical trial, TAK-079 is being evaluated for safety, tolerability, pharmacokinetics, and efficacy in patients with primary IgA nephropathy who are receiving stable background therapy.

The IgA Nephropathy Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of IgA Nephropathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for IgA Nephropathy Treatment.
• IgA Nephropathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• IgA Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the IgA Nephropathy market.

Learn more about IgA Nephropathy Drugs opportunities in our groundbreaking IgA Nephropathy research and development projects @ IgA Nephropathy Unmet Needs- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

IgA Nephropathy Companies
Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Selecta Biosciences, and Shanghai Alebund Pharmaceuticals and others.

IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

IgA Nephropathy Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in IgA Nephropathy treatment by visiting our website. Stay informed about how we're transforming the future of Genito Urinary System and Sex Hormones @ IgA Nephropathy Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the IgA Nephropathy Pipeline Report
• Coverage- Global
• IgA Nephropathy Companies- Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Selecta Biosciences, and Shanghai Alebund Pharmaceuticals and others.
• IgA Nephropathy Pipeline Therapies- LNP023, Blisibimod, Intravenous Rituximab, BION-1301, Atrasentan, TARPEYO®, HRS-5965 and others.
• IgA Nephropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• IgA Nephropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of IgA Nephropathy Pipeline on our website @ IgA Nephropathy Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. IgA Nephropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. IgA Nephropathy- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Atrasentan: Chinook Therapeutics
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. SHR-2010: Guangdong Hengrui Pharmaceutical Co., Ltd.
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. TAK-079: Takeda
15. Preclinical and Discovery Stage Products
16. Product Name: Company Name
17. Inactive Products
18. IgA Nephropathy Key Companies
19. IgA Nephropathy Key Products
20. IgA Nephropathy- Unmet Needs
21. IgA Nephropathy- Market Drivers and Barriers
22. IgA Nephropathy- Future Perspectives and Conclusion
23. IgA Nephropathy Analyst Views
24. IgA Nephropathy Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.